CATEGORIES: Research
2019 HNF Donations

Won’t You Please Consider A Year End Gift?

by | Dec 23, 2019 | 0 comments

We Put Your Donations to Work in 2019!

1) HNF developed a new program called Movement is Medicine™, launching an annual Summit that supports patients through exercise therapies

2) Hosted the first Pediatric Neuromuscular CMT Expert Roundtable to advance care and target therapies for our CMT kids

3) Advanced pediatric therapies by funding (with a generous match from U Penn) a clinical study: Correlation between gait abnormalities, activity monitoring parameters, CMTPed Score and a biomarker in children with CMT

4) Developed 15 new Patient Focused Educational CMT-Connect Webinars

5) Added additional CMT types to the HNF Therapeutic Research In Accelerated Discovery (TRIAD) Gene Therapy Program 

6) Developed 2 Patient-Reported Outcomes (PROs) Studies through the Global Registry for Inherited Neuropathies (GRIN) to advance CMT therapies as well as presented important findings at major medical conferences across the globe

8) Hosted the “Take a Look at This Heart” documentary screening in New York City to shed light on disability and intimacy

9) Added 3 additional HNF Centers of Excellence; we now have 17 designated sites in total to support patient care, research and clinical trials 

10) Increased awareness through CME Educational Courses to assess and advance knowledge of CMT amongst medical professionals 

11) Vetted and added over 450 more health care providers to HNFs Health Care Provider Directory to provide care to our patient community 

12) Held multiple TEAM CMT events – providing more opportunities than ever for donor engagement through Movement is Medicine™ fundraisers: TCS NYC Marathon, TD Five Boro Bike Tour/Bike New York, Philadelphia Million Dollar Bike Ride, and Coast to Coast Spin-a-Thons

13) Expanded our Therapeutic Research In Accelerated Discovery (TRIAD) program – HNF approved the development of additional cellular assays, animal models and clinical studies to tackle research gaps and advance therapies

14) Grew our thriving CMT Inspire Community with increased peer-to-peer support – we are now close to 7000 members strong

15) Continued to engage in FDA regulatory issues to address drug  development for CMT. HNF’s FDA Clinical Path Innovation Meeting (CPIM) provided a case study on innovative voice technology to incorporate Patient Reported Outcomes (PROs) for clinical trials and studies

Learn more on this topic

Related Blog Posts

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news